TUDORZA PRESSAIR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TUDORZA PRESSAIR (TUDORZA PRESSAIR).
Long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation.
| Metabolism | Primarily hydrolyzed via esterases in plasma and tissues; not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily non-renal elimination: 54% of the radiolabeled dose recovered in feces, 28% in urine after 7 days. Fecal excretion likely represents unabsorbed drug and biliary elimination. |
| Half-life | Terminal elimination half-life approximately 10 hours, supporting twice-daily dosing in chronic obstructive pulmonary disease. |
| Protein binding | Binding to human plasma proteins is approximately 72%. |
| Volume of Distribution | Volume of distribution at steady state is 165 L (approx. 2.4 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Absolute bioavailability after inhalation is not known; systemic exposure is low due to high local lung deposition and rapid clearance. |
| Onset of Action | Time to bronchodilation onset is within 30 minutes after inhalation; maximum effect seen at 2 hours. |
| Duration of Action | Bronchodilator effect persists for 12 hours, consistent with twice-daily dosing regimen. |
| Molecular Weight | 490.4 |
One inhalation (400 mcg aclidinium) orally twice daily.
| Dosage form | POWDER, METERED |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C), use caution. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No dose adjustment required; plasma concentrations similar to younger adults. |
| 1st trimester | Limited human data; animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Use only if potential benefit justifies risk. |
| 2nd trimester | Limited human data; no evidence of teratogenicity. Consider risk-benefit for women with asthma not controlled by other agents. |
| 3rd trimester | Avoid during labor as tiotropium may interfere with uterine contractility. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for TUDORZA PRESSAIR (TUDORZA PRESSAIR).
| Placental transfer | Tiotropium bromide crosses the placenta in rats; extent in humans is unknown. Molecular weight (490.4 Da) suggests potential for placental transfer. |
| Breastfeeding | Tiotropium is excreted in human milk in trace amounts. Effects on the breastfed infant are unlikely but caution advised due to potential anticholinergic effects. Use only if clinically necessary. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to tiotropium bromide or any component of the formulationHistory of hypersensitivity to atropine or its derivatives
| Precautions | Not for acute bronchospasm or initial therapy of acute episodes, Paradoxical bronchospasm may occur, Immediate hypersensitivity reactions reported, Use with caution in narrow-angle glaucoma, Use with caution in urinary retention (e.g., prostatic hyperplasia, bladder neck obstruction) |
| Food/Dietary | No clinically significant food interactions. However, avoid grapefruit juice as it may theoretically affect CYP3A4 metabolism (minor relevance). No dietary restrictions specifically required. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at exposures up to 100 times the maximum recommended human daily inhalation dose. Risk of fetal harm cannot be ruled out. Use during pregnancy only if clearly needed. |
| Fetal Monitoring | Monitor for signs of bronchospasm, respiratory distress, and anticholinergic effects (e.g., blurred vision, urinary retention). No specific fetal monitoring required beyond routine prenatal care. |
| Fertility Effects | No human data on fertility. Animal studies with tiotropium showed no impairment of fertility at doses up to 0.335 mg/kg/day (approximately 10 times the maximum recommended human daily inhalation dose on a mg/m2 basis). |
| Clinical Pearls |
| TUDORZA PRESSAIR (aclidinium bromide) is a long-acting muscarinic antagonist (LAMA) for maintenance treatment of COPD. It should not be used for acute bronchospasm. Administer via the Pressair inhaler; ensure patient can hear the click indicating dose is ready. Advise patient to rinse mouth with water after each dose to reduce risk of paradoxical bronchospasm and oropharyngeal side effects. Use with caution in patients with narrow-angle glaucoma, urinary retention, or severe renal impairment (CrCl <30 mL/min). |
| Patient Advice | Use TUDORZA PRESSAIR exactly as prescribed: one inhalation twice daily (morning and evening). · Do not use for sudden breathing problems; have a rescue inhaler (e.g., albuterol) available. · Rinse your mouth with water after each use to prevent dry mouth and throat irritation. · Do not swallow the capsule; the medicine is for inhalation only using the Pressair device. · If you forget a dose, skip it and take the next dose at the usual time; do not double dose. · Seek immediate medical help if you experience chest pain, difficulty urinating, or vision changes. · Tell your doctor if you have glaucoma, prostate problems, or kidney disease. · Keep the inhaler clean and store at room temperature away from moisture and heat. |